Abstract: The gun sight comprises a cathode ray tube (21) to generate an aiming image and optical means (22,23) to project said generated image into a line of sight through the gun sight. Velocity of movement of the gun sight is sensed by gyros and in response thereto the cathode ray tube (21) generates an aiming image at a location displaced from a sight-stationary position by an amount dependent on the velocity and direction of movement of the gun sight and a predetermined target range.

Abstract: Prostaglandin (PG.sub.1) derivatives having a 5,6-didehydro feature, for example an enol ether of the formula ##STR1## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

Abstract: The present invention relates to 2-decarboxy-2-tetrazolyl-PGI.sub.2 amides, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to PGI.sub.2 pharmacologically acceptable salts, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to PGI.sub.2 lower alkyl esters, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to 2-decarboxy-2-hydroxymethyl-PGI.sub.2 compounds, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to 2-decarboxy-2-aminomethyl-PGI.sub.2 compounds, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to PGI.sub.2 analogs, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to PGI.sub.2 amides, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.

Abstract: The present invention relates to PGI.sub.2 11,15-ether intermediates, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors. The present invention describes PGI.sub.2 11,15-ether intermediates. These compounds are intermediates for preparing corresponding prostacylcin-type compounds with pharmacological utility, e.g., platelet aggregation inhibitors.

Abstract: Prostaglandin E.sub.1 -type and F.sub.1 -type compounds with a methyl or an ethyl substituent at the C-15 position are disclosed. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins.

Abstract: Prostaglandin A.sub.1 compounds with a methyl or an ethyl substituent at the C-15 position are disclosed. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins A.

Abstract: This invention is a group of optically active or racemic prostaglandin E.sub.1 analogs of the formula: ##SPC1##Wherein R is an alkyl group containing from one to 8 carbon atoms, inclusive, X is hydrogen or methyl with the proviso that not more than one methyl group can be present in a given side chain, Y and Y' are hydrogen or alkanoyl of one to 12 carbon atoms, inclusive, Z is hydrogen, a hydrocarbyl group of one to 12 carbon atoms, inclusive, or a pharmacologically acceptable cation, and n is 0, 1 or 2. These prostaglandin E.sub.1 analogs are useful for the same pharmacological purposes as PGE.sub.1.

Abstract: Intermediates useful for preparing prostaglandin-type compounds with an alkoxy group replacing the hydroxyl at the C-15 position are disclosed. These products are useful for the same pharmacological properties as the unsubstituted prostaglandins.

Abstract: Prostaglandin E.sub.1 -type, F.sub.1 -type, A.sub.1 -type, and B.sub.1 -type compounds with one or two methyl or ethyl substituents at the C-16 position are disclosed. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins.

Abstract: Prostaglandins E.sub.1 -type and F.sub.1 -type compounds of the formula ##EQU1## wherein R is hydrogen or a hydrocarbyl group containing from 1 to 12 carbon atoms, inclusive, wherein W is ##EQU2## or O =, wherein R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 are hydrogen or alkyl of 1 to 4 carbon atoms, inclusive, provided (1) that at least one of R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 is alkyl (2) that when R.sub.13 is alkyl, at least one of R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, and R.sub.14 is alkyl, and (3) that when R.sub.7 is alkyl or thwn R.sub.7 and R.sub.8 are alkyl, at least one of R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 is alkyl; and the enantiomers and racemic mixtures thereof. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins.

Abstract: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

Abstract: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

Abstract: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

Abstract: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..